Pelthos Therapeutics Inc. 8-K — AI Bull & Bear Analysis

The 8-K filing confirms Pelthos Therapeutics is entering a critical window of investor relations, utilizing a major industry conference to bridge the gap between its current development stage and future funding needs. While the move provides a catalyst for potential stock price appreciation if institutional interest is sparked, it also highlights the company's ongoing dependence on external capital markets. Investors are now weighing the potential for a strategic partnership against the likelihood of a dilutive financing event.